WHO Classification of Tumours Editorial BoardWHO Classification of Tumours: Central Nervous System Tumours. 5th edition. World Health Organization, Ostrom Q.T. Patil N. Cioffi G. et al.

CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017.

Neuro Oncol. 22: IV1-IV96Ostrom Q.T. Rubin J.B. Lathia J.D. et al.

Females have the survival advantage in glioblastoma.

Neuro Oncol. 20: 576Gittleman H. Ostrom Q.T. Stetson L.C. et al.

Sex is an important prognostic factor for glioblastoma but not for nonglioblastoma.

Neurooncol Pract. 6: 451-462Gittleman H. Boscia A. Ostrom Q.T. et al.

Survivorship in adults with malignant brain and other central nervous system tumor from 2000-2014.

Neuro Oncol. 20: VII6-VII16Wang G.M. Cioffi G. Patil N. et al.

Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas.

Neuro Oncol. 24: 302-310Massey S.C. Whitmire P. Doyle T.E. et al.

Sex differences in health and disease: A review of biological sex differences relevant to cancer with a spotlight on glioma.

Cancer Lett. 498: 178-187Yang W. Warrington N.M. Taylor S.J. et al.

Sex differences in GBM revealed by analysis of patient imaging, transcriptome, and survival data.

Sci Transl Med. 11https://doi.org/10.1126/SCITRANSLMED.AAO5253/SUPPL_FILE/AAO5253_TABLES_S1_TO_S12Su C.Y. Li J.Q. Zhang L.L. et al.

The Biological Functions and Clinical Applications of Integrins in Cancers.

Front Pharmacol. 11: 1435Sun T. Plutynski A. Ward S. et al.

An integrative view on sex differences in brain tumors.

Cell Mol Life Sci. 72: 3323Rockwell N.C. Yang W. Warrington N.M. et al.

Sex- and Mutation-Specific p53 Gain-of-Function Activity in Gliomagenesis.

Cancer Res Commun. 1: 148-163Colen R.R. Wang J. Singh S.K. et al.

Glioblastoma: imaging genomic mapping reveals sex-specific oncogenic associations of cell death.

Radiology. 275: 215-227Casey S.C. Baylot V. Felsher D.W.

The MYC oncogene is a global regulator of the immune response.

Blood. 131: 2007-2015Sun T. Warrington N.M. Luo J. et al.

Sexually dimorphic RB inactivation underlies mesenchymal glioblastoma prevalence in men.

J Clin Invest. 124: 4123-4133Yust-Katz S. De Groot J.F. Liu D. et al.

Pregnancy and glial brain tumors.

Neuro Oncol. 16: 1289-1294

Antiangiogenic therapies in glioblastoma multiforme.

Expert Rev Anticancer Ther. 12: 643-654Couldwell W. Hinton D. Surnock A. et al.

Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen.

Clin Cancr Res. 2: 619-622Yang P. Zhang W. Wang Y. et al.

IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.

Oncotarget. 6: 40896-40906Schiffgens S. Wilkens L. Brandes A.A. et al.

Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma.

Oncotarget. 7: 55169Brat D.J. Aldape K. Colman H. et al.

cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV.

Acta Neuropathol. 136: 805-810Xu H. Zong H. Ma C. et al.

Epidermal growth factor receptor in glioblastoma.

Oncol Lett. 14: 512Dratwa M. Wysoczańska B. Łacina P. et al.

TERT—Regulation and Roles in Cancer Formation.

Front Immunol. 11https://doi.org/10.3389/FIMMU.2020.589929Ostrom Q.T. Coleman W. Huang W. et al.

Sex-specific gene and pathway modeling of inherited glioma risk.

Neuro Oncol. 21: 71-82Ostrom Q.T. Kinnersley B. Wrensch M.R. et al.

Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21.

Sci Rep. 8: 1-15Stupp R. Mason W.P. van den Bent M.J. et al.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

N Engl J Med. 352: 987-996Stupp R. Taillibert S. Kanner A. et al.

Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial.

JAMA. 318: 2306-2316Gerber D.E. Grossman S.A. Zeltzman M. et al.

The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas.

Neuro Oncol. 9: 47Gupta T. Mohanty S. Moiyadi A. et al.

Factors predicting temozolomide induced clinically significant acute hematologic toxicity in patients with high-grade gliomas: a clinical audit.

Clin Neurol Neurosurg. 115: 1814-1819Matteoni S. Abbruzzese C. Villani V. et al.

The influence of patient sex on clinical approaches to malignant glioma.

Cancer Lett. 468: 41-47Stupp R. Hegi M.E. Gorlia T. et al.

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.

Lancet Oncol. 15: 1100-1108Bhala S. Stewart D.R. Kennerley V. et al.

Incidence of benign meningiomas in the United States: current and future trends.

JNCI Cancer Spectr. 5https://doi.org/10.1093/JNCICS/PKAB035Klaeboe L. Lonn S. Scheie D. et al.

Incidence of intracranial meningiomas in Denmark, Finland, Norway and Sweden, 1968-1997.

Int J Cancer. 117: 996-1001Commins D.L. Atkinson R.D. Burnett M.E.

Review of meningioma histopathology.

Neurosurg Focus. 23: E3Hsu D.W. Efird J.T. Hedley-Whyte E.T.

Progesterone and estrogen receptors in meningiomas: prognostic considerations.

J Neurosurg. 86: 113-120Harland T.A. Freeman J.L. Davern M. et al.

Progesterone-only contraception is associated with a shorter progression-free survival in premenopausal women with WHO Grade I meningioma.

J Neurooncol. 136: 327-333Peyre M. Gaillard S. de Marcellus C. et al.

Progestin-associated shift of meningioma mutational landscape.

Ann Oncol Off J Eur Soc Med Oncol. 29: 681-686Blitshteyn S. Crook J.E. Jaeckle K.A.

Is there an association between meningioma and hormone replacement therapy?.

J Clin Oncol. 26: 279-282Benson V.S. Kirichek O. Beral V. et al.

Menopausal hormone therapy and central nervous system tumor risk: large UK prospective study and meta-analysis.

Int J Cancer. 136: 2369-2377Benson V.S. Pirie K. Green J. et al.

Hormone replacement therapy and incidence of central nervous system tumours in the Million Women Study.

Int J Cancer. 127: 1692-1698Korhonen K. Raitanen J. Isola J. et al.

Exogenous sex hormone use and risk of meningioma: a population-based case-control study in Finland.

Cancer Causes Control. 21: 2149-2156Lee E. Grutsch J. Persky V. et al.

Association of meningioma with reproductive factors.

Int J Cancer. 119: 1152-1157Claus E.B. Calvocoressi L. Bondy M.L. et al.

Exogenous hormone use, reproductive factors, and risk of intracranial meningioma in females.

J Neurosurg. 118: 649Ji Y. Rankin C. Grunberg S. et al.

Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005.

J Clin Oncol. 33: 4093Goodwin J.W. Crowley J. Eyre H.J. et al.

A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study.

J Neurooncol. 15: 75-77Champeaux-Depond C. Weller J. Froelich S. et al.

Cyproterone acetate and meningioma: a nationwide-wide population based study.

J Neurooncol. 151: 331-338Hage M. Plesa O. Lemaire I. et al.

Estrogen and Progesterone Therapy and Meningiomas.

Endocrinology. 163Shahin M.N. Magill S.T. Dalle Ore C.L. et al.

Fertility treatment is associated with multiple meningiomas and younger age at diagnosis.

J Neurooncol. 143: 137Lusis E.A. Scheithauer B.W. Yachnis A.T. et al.

Meningiomas in pregnancy: a clinicopathologic study of 17 cases.

Neurosurgery. 71: 951-961Wigertz A. Lönn S. Hall P. et al.

Reproductive factors and risk of meningioma and glioma.

Cancer Epidemiol Biomarkers Prev. 17: 2663-2670Michaud D.S. Gallo V. Schlehofer B. et al.

Reproductive factors and exogenous hormone use in relation to risk of glioma and meningioma in a large European cohort study.

Cancer Epidemiol Biomarkers Prev. 19: 2562-2569Owens M.A. Craig B.M. Egan K.M. et al.

Birth desires and intentions of women diagnosed with a meningioma.

J Neurosurg. 122: 1151Cowppli-Bony A. Bouvier G. Rué M. et al.

Brain tumors and hormonal factors: review of the epidemiological literature.

Cancer Causes Control. 22: 697-714Schlehofer B. Blettner M. Wahrendorf J.

Association between brain tumors and menopausal status.

J Natl Cancer Inst. 84: 1346-1349

Fertility and pregnancy in cancer survivors.

Obstet Med. 11: 110Molina J.R. Barton D.L. Loprinzi C.L.

Chemotherapy-induced ovarian failure.

Drug Saf. 28: 401-416

Effect of cytotoxic therapy on sexuality and gonadal function.

Semin Oncol. 9: 84-94Imai A. Ichigo S. Matsunami K. et al.

Ovarian function following targeted anti-angiogenic therapy with bevacizumab (Review).

Mol Clin Oncol. 6: 807-810Greenberg T.D. Hoff M.N. Gilk T.B. et al.

ACR guidance document on MR safe practices: Updates and critical information 2019.

J Magn Reson Imaging. 51: 331-338

Guidelines for diagnostic imaging during pregnancy and lactation.

Obstet Gynecol. 130: e210-e216

Abdominal Imaging in pregnancy (maternal and foetal risks).

Best Pract Res Clin Gastroenterol. : 44-45

723: guidelines for diagnostic imaging during pregnancy and lactation: correction.

Obstet Gynecol. 132: 786Gatta G. Di Grezia G. Cuccurullo V. et al.

MRI in pregnancy and precision medicine: a review from literature.

J Pers Med. 12Güveli B.T. Rosti R.Ö. Güzeltaş A. et al.

Teratogenicity of antiepileptic drugs.

Clin Psychopharmacol Neurosci. 15: 19